000 02388cam a2200349 a 4500
003 EG-GiCUC
005 20250223032329.0
008 190716s2019 ua d f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.19.03.Ph.D.2019.He.D
100 0 _aHend Abdelhady Nooh Mahmood
245 1 0 _aDetection of IDH1 and IDH2 mutations in denovo acute myeloid leukemia patients at National Cancer Institute, Cairo University /
_cHend Abdelhady Nooh Mahmood ; Supervised Ragia H. Badawy , Yasser H. Elnahhas , Fatma A. Elrefaey
246 1 5 _aفي حالات سرطان الدم الميلودي الحاد الحديثة التشخيص بالمعهد القومي للاورام - جامعة القاهرة Isocitrate Dehydrogenase (IDH 1,2) كشف الطفرة الجينيه لجيني
260 _aCairo :
_bHend Abdelhady Nooh Mahmood ,
_c2019
300 _a187 P. :
_bcharts ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology
520 _aIntroduction: AML is characterized by the uncontrolled clonal proliferation of poorly differentiated cells of myeloblasts. Isocitrate dehydrogenases (IDH1&2) are enzymes involved in multiple metabolic and epigenetic cellular processes. Mutations in IDH1 or IDH2 induce production of an oncometabolite, 2-hydroxyglutarate (R-2-HG) which leads to DNA hypermethylation, and abnormal differentiation. IDH mutations diversely affect prognosis of patients with AML based on the presence of other co-occurring genomic abnormalities. Aim of the work : The aim of this study was to assess the frequency of IDH1& IDH2 genes mutations in AML patients and evaluate their role in disease prognosis. Patients and Methods: We analyzed IDH mutations in 70 denovo AML patients (exon 4 for IDH1& exon 4 for IDH2) using High Resolution Melting (HRM) curve analysis
530 _aIssued also as CD
653 4 _aAML (Acute Myeloid Leukemia)
653 4 _aIDH (Isociterate Dehydrogenase)
653 4 _aKaryotype
700 0 _aFatma A. Elrefaey ,
_eSupervisor
700 0 _aRagia H. Badawy ,
_eSupervisor
700 0 _aYasser H. Elnahhas ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aShimaa
_eCataloger
942 _2ddc
_cTH
999 _c72892
_d72892